Capital Advisors Ltd. LLC Buys 95 Shares of Becton, Dickinson and Company (NYSE:BDX)

Capital Advisors Ltd. LLC raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 7.1% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 1,428 shares of the medical instruments supplier’s stock after acquiring an additional 95 shares during the quarter. Capital Advisors Ltd. LLC’s holdings in Becton, Dickinson and Company were worth $324,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently made changes to their positions in BDX. Bank of Jackson Hole Trust bought a new position in shares of Becton, Dickinson and Company in the fourth quarter worth about $25,000. Sierra Ocean LLC bought a new position in Becton, Dickinson and Company in the 4th quarter valued at approximately $29,000. Ashton Thomas Securities LLC bought a new position in Becton, Dickinson and Company in the 3rd quarter valued at approximately $33,000. Tompkins Financial Corp raised its holdings in Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after buying an additional 46 shares during the last quarter. Finally, Kennebec Savings Bank bought a new position in Becton, Dickinson and Company in the 3rd quarter valued at approximately $46,000. Institutional investors own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In related news, EVP Roland Goette sold 4,483 shares of Becton, Dickinson and Company stock in a transaction on Friday, December 6th. The shares were sold at an average price of $221.01, for a total value of $990,787.83. Following the completion of the sale, the executive vice president now owns 24,345 shares of the company’s stock, valued at approximately $5,380,488.45. This trade represents a 15.55 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, EVP David Shan sold 500 shares of Becton, Dickinson and Company stock in a transaction on Tuesday, January 21st. The shares were sold at an average price of $240.00, for a total transaction of $120,000.00. Following the completion of the sale, the executive vice president now directly owns 5,741 shares of the company’s stock, valued at approximately $1,377,840. The trade was a 8.01 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 10,544 shares of company stock valued at $2,370,309 in the last quarter. 0.36% of the stock is currently owned by company insiders.

Becton, Dickinson and Company Stock Up 1.3 %

Becton, Dickinson and Company stock opened at $230.40 on Tuesday. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.63 and a current ratio of 1.13. Becton, Dickinson and Company has a 52-week low of $218.75 and a 52-week high of $251.99. The firm has a 50 day moving average price of $232.96 and a two-hundred day moving average price of $233.25. The firm has a market cap of $66.16 billion, a price-to-earnings ratio of 38.27, a PEG ratio of 1.63 and a beta of 0.40.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. Equities analysts predict that Becton, Dickinson and Company will post 14.43 EPS for the current year.

Becton, Dickinson and Company announced that its board has initiated a stock repurchase plan on Tuesday, January 28th that allows the company to repurchase 10,000,000 shares. This repurchase authorization allows the medical instruments supplier to reacquire shares of its stock through open market purchases. Shares repurchase plans are often an indication that the company’s management believes its stock is undervalued.

Becton, Dickinson and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Monday, March 31st. Stockholders of record on Monday, March 10th will be given a dividend of $1.04 per share. This represents a $4.16 annualized dividend and a dividend yield of 1.81%. The ex-dividend date of this dividend is Monday, March 10th. Becton, Dickinson and Company’s dividend payout ratio (DPR) is 69.10%.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. StockNews.com upgraded shares of Becton, Dickinson and Company from a “hold” rating to a “buy” rating in a report on Wednesday, February 12th. Piper Sandler raised their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the company an “overweight” rating in a report on Tuesday, January 28th. Finally, Barclays raised their price objective on shares of Becton, Dickinson and Company from $278.00 to $279.00 and gave the company an “overweight” rating in a report on Friday, February 14th. Eight analysts have rated the stock with a buy rating, Based on data from MarketBeat, Becton, Dickinson and Company presently has an average rating of “Buy” and a consensus price target of $278.29.

About Becton, Dickinson and Company

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.